Loading organizations...
Albany Capital operates as a private investment group, deploying capital into future-facing industries. The firm prioritizes sectors leveraging transformational technology, focusing primarily on the intersection of health and technology, alongside sustainability and digital innovation. Its model involves identifying and supporting companies developing groundbreaking solutions within these domains, providing investment and strategic guidance.
Information regarding Albany Capital’s founders, its precise establishment date, and the foundational insight that led to its creation is not publicly detailed on its official platforms or readily available. This aspect of the firm’s origin story remains undisclosed in public records, consistent with its private investment structure.
Albany Capital actively partners with companies striving for positive global impact through technological advancements. Its vision is to cultivate innovation directly addressing critical challenges within health, environmental sustainability, and the digital landscape. The firm commits to collaborating with enterprises that align with its core mission of contributing to a more beneficial future.
Albany Capital has 1 tracked investment across 1 company. The latest tracked deal is $80.0M Series B in Sherlock Biosciences in March 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 8, 2022 | Sherlock Biosciences | $80.0M Series B | Paul Meister | Catalio Capital, Illumina Ventures |